Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1110

Showing 1-25 of 1110 citing articles:

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. S140-S157
Open Access | Times Cited: 658
Type 2 diabetes
Ehtasham Ahmad, Soo Lim, Roberta Lamptey, et al.
The Lancet (2022) Vol. 400, Iss. 10365, pp. 1803-1820
Closed Access | Times Cited: 533
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S158-S178
Open Access | Times Cited: 282
5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. S68-S96
Open Access | Times Cited: 269
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Julio Rosenstock, Juan P. Frías, Ania M. Jastreboff, et al.
The Lancet (2023) Vol. 402, Iss. 10401, pp. 529-544
Closed Access | Times Cited: 205
American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update
Susan L. Samson, Priyathama Vellanki, Lawrence Blonde, et al.
Endocrine Practice (2023) Vol. 29, Iss. 5, pp. 305-340
Open Access | Times Cited: 188
Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention
Nathan D. Wong, Naveed Sattar
Nature Reviews Cardiology (2023) Vol. 20, Iss. 10, pp. 685-695
Closed Access | Times Cited: 161
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. s49-s67.2
Open Access | Times Cited: 144
5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S77-S110
Open Access | Times Cited: 133
GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
Riccardo Nevola, Raffaella Epifani, Simona Imbriani, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1703-1703
Open Access | Times Cited: 120
What is the pipeline for future medications for obesity?
Eka Melson, Uzma Ashraf, Dimitris Papamargaritis, et al.
International Journal of Obesity (2024)
Open Access | Times Cited: 101
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin
Julio Rosenstock, Stephen C. Bain, Amoolya Gowda, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 4, pp. 297-308
Open Access | Times Cited: 86
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
Brendon L. Neuen, Hiddo J.L. Heerspink, Priya Vart, et al.
Circulation (2023) Vol. 149, Iss. 6, pp. 450-462
Open Access | Times Cited: 86
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
Stephen J. Nicholls, Deepak L. Bhatt, John B. Buse, et al.
American Heart Journal (2023) Vol. 267, pp. 1-11
Open Access | Times Cited: 79
Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes
Ildiko Lingvay, Marisse Asong, Cyrus Desouza, et al.
JAMA (2023) Vol. 330, Iss. 3, pp. 228-228
Open Access | Times Cited: 77
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S52-S76
Open Access | Times Cited: 70
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: SOUL , a randomized trial, design and baseline characteristics
Darren K. McGuire, Rodica Pop‐Busui, John Deanfield, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 7, pp. 1932-1941
Open Access | Times Cited: 69
Current insights and emerging trends in early-onset type 2 diabetes
Shivani Misra, Calvin Ke, Shylaja Srinivasan, et al.
The Lancet Diabetes & Endocrinology (2023) Vol. 11, Iss. 10, pp. 768-782
Closed Access | Times Cited: 66
Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes
Siddhartha Dutta, Rima Shah, Shubha Singhal, et al.
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 1907-1932
Open Access | Times Cited: 64
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
Vanita R. Aroda, Jens Aberle, Lars Bardtrum, et al.
The Lancet (2023) Vol. 402, Iss. 10403, pp. 693-704
Open Access | Times Cited: 60
Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
Pierre Gourdy, Patrice Darmon, François Diévart, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 51
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
Leili Gao, Byung‐Wan Lee, Manoj Chawla, et al.
Nature Medicine (2023) Vol. 29, Iss. 6, pp. 1500-1510
Open Access | Times Cited: 50
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial
Kausik K. Ray, Stephen J. Nicholls, Na Li, et al.
The Lancet Diabetes & Endocrinology (2023) Vol. 12, Iss. 1, pp. 19-28
Open Access | Times Cited: 45
The role of structural racism and geographical inequity in diabetes outcomes
Shivani Agarwal, Alisha N. Wade, Jean Claude Mbanya, et al.
The Lancet (2023) Vol. 402, Iss. 10397, pp. 235-249
Open Access | Times Cited: 41
Time in Tight Glucose Range in Type 1 Diabetes: Predictive Factors and Achievable Targets in Real-World Users of the MiniMed 780G System
Javier Castañeda, Arcelia Arrieta, Tim van den Heuvel, et al.
Diabetes Care (2023) Vol. 47, Iss. 5, pp. 790-797
Open Access | Times Cited: 41
Page 1 - Next Page

Scroll to top